Results from the XTEND-Kids study show the potential of ALTUVIIIO in severe hemophilia A

Sanofi-Aventis announces the publication, in the New England Journal of Medicine, of phase III data from the XTEND-Kids study. The results show that ALTUVIIIO, administered once a week, achieves sustained levels of factor VIII expression in children with severe hemophilia A. The drug provides effective protection against bleeding, without the development of factor VIII inhibitors.

The study, involving 73 participants, found a median annualized bleeding rate of 0.00. No joint bleeding was observed in 82% of treated children, demonstrating the potential of ALTUVIIIO to sustainably protect joint health. ALTUVIIIO was well tolerated, with side effects mainly related to mild infections.